Article thumbnail

Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia

By Douglas L Noordsy, Glenn A Phillips, Daniel E Ball and Walter T Linde-Zwirble
Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2915559
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia.
  2. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.
  3. (2009). Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population. Curr Med Res Opin.
  4. Cost of relapse in schizophrenia.
  5. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled posthoc analysis of four atypical antipsychotic drugs.
  6. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
  7. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
  8. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
  9. Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls.
  10. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.
  11. (2000). Improving health-based payment for Medicaid beneficiaries: CDPS. Health Care Financ Rev.
  12. Non-adherence to antipsychotic medication regimens: associations with resource use and costs.
  13. (2004). Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv.
  14. (2009). Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin.
  15. Relapse in schizophrenia: costs, clinical outcomes and quality of life.
  16. Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication.
  17. (2004). The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health.
  18. (2001). Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv.
  19. What is relapse in schizophrenia?